<< Boston Scientific announces launch of Neuroform EZ Stent System in U.S. and Europe | Rite Aid agrees to pay $1 million to settle medical privacy questions >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

Response Biomedical closes $8 million common share private placement

Published on July 29, 2010 at 1:17 AM · No Comments

Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) (the "Company") announced today that it has closed its previously announced private placement of common shares for gross proceeds of approximately $8 million. The Company issued 13,333,333 common shares at a price of C$0.60 per share.

The purchasers are affiliates of OrbiMed Advisors, LLC.

The shares issued under the private placement will have a hold period under Canadian law of four months and one day from the closing. Net proceeds of the private placement will be used primarily for general operating expenses.

The offer and sale of the securities described herein have not been registered under the U.S. Securities Act of l933, as amended, or any state securities laws and may not be offered or sold in the United States or to U.S. persons unless an exemption from registration is available.

SOURCE Response Biomedical Corporation

Posted in:

Tags: , , , , , , , ,

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading